Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will present and host investor meetings at multiple January investor conferences, including the Sachs Associates 9th Annual Neuroscience Innovation Forum and Biotech Showcase 2026, both held in San Francisco. President and Chief Executive Officer Seth Lederman, M.D., is scheduled to deliver a company presentation and participate in a panel discussion focused on neuropsychiatric drug development at the Sachs Associates forum, and to present at Biotech Showcase 2026, with a replay of the presentation expected to be made available on the company’s website following the event.
Tonix is a fully-integrated biotechnology company with marketed products and a pipeline of development candidates. The company markets FDA-approved TONMYA (TNX-102 SL), a first-in-class, non-opioid analgesic for fibromyalgia, which affects millions of adults. TONMYA is the first new prescription medicine approved by the FDA for fibromyalgia in more than 15 years. Tonix also markets two treatments for acute migraine in adults: Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray).
Tonix’s development portfolio is focused on central nervous system (CNS) disorders, immunology, immuno-oncology, rare disease and infectious disease. TNX-102 SL is being developed to treat acute stress reaction and acute stress disorder under an Investigator-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). TNX-102 SL is also in development for major depressive disorder. The immunology portfolio includes TNX-1500, a Phase 2-ready Fc-modified humanized monoclonal antibody targeting CD40-ligand, being developed for prevention of allograft rejection and treatment of autoimmune diseases. The rare disease portfolio includes TNX-2900, intranasal oxytocin potentiated with magnesium, in development for Prader-Willi syndrome and expected to start a potential pivotal Phase 2 study in 2026. The infectious disease portfolio includes TNX-801, a vaccine for mpox and smallpox, and TNX-4800, a Phase 2-ready long-acting humanized monoclonal antibody for seasonal prevention of Lyme disease. Additionally, TNX-4200, for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years, is a small molecule broad-spectrum antiviral agent targeting CD45 for prevention or treatment of high lethality infections.
The company’s participation in these conferences signals its commitment to advancing its pipeline and engaging with the investment community. The full press release is available at https://ibn.fm/l7Ohq. For the latest news on TNXP, visit the company’s newsroom at https://ibn.fm/TNXP.
